SMS Lifescience India has acquired 28,15,100 equity shares of Rs 10 each (59.70%) in Mahi Drugs on August 02, 2018. With this, the total stake of the company as on date in Mahi Drugs amounts to 78.79%.
SMS Lifesciences India is engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, Active Pharmaceutical Ingredients (API) and Intermediates.